^
Association details:
| Biomarker: | KRAS mutation |
|---|---|
| Cancer: | Colorectal Cancer |
| Drug: | eltanexor (KPT-8602) (XPO1 inhibitor, Nuclear export inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Eltanexor (KPT-8602), a second-generation selective inhibitor of nuclear export (SINE) compound, in patients with metastatic colorectal cancer (mCRC)
Excerpt:
Pts with mCRC (≥50% KRAS mutant) in expansion cohorts received once daily oral ELTAfor 5 days per week at 20 (n = 7) or 30 (n = 23) mg….ELTA is well-tolerated with manageable AEs in mCRC. Even though this was small sample size, ELTA shows promise with a longer median PFS in this heavily treated population when compared to the currently available 3rdline therapies.
DOI:
10.1093/annonc/mdy424.024
Trial ID:
